Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Nbuvb

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Early Phase 1 (1)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03932162Early Phase 1RecruitingPrimary

Gene Expression Changes In Young and Geriatric Skin

NCT05647187Not ApplicableCompleted

Effect Narrow-Band UVB Radiations

Showing all 2 trials

Research Network

Common Treatments

  • Nbuvb1
  • No Insulinlie Growth Factor 11
  • Insulinlike Growth Factor 11
  • Serum Interleukin 17 Levels1

Active Sponsors

  • Wright State University1
  • South Valley University1

Top Investigators

Related Conditions

  • Aging1
  • Psoriasis Vulgaris1
  • Insulinlike Growth Factor 11

Activity Timeline